These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

297 related items for PubMed ID: 25104092

  • 1. Heterozygote advantage of methylenetetrahydrofolate reductase polymorphisms on clinical outcomes in advanced non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy.
    Li X, Shao M, Wang S, Zhao X, Chen H, Qian J, Song X, Wang J, Jin L, Wu J, Li Q, Bai C, Han B, Gao Z, Lu D.
    Tumour Biol; 2014 Nov; 35(11):11159-70. PubMed ID: 25104092
    [Abstract] [Full Text] [Related]

  • 2. Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict platinum-based chemotherapy response of advanced non-small cell lung cancers in a Chinese population.
    Xu JL, Wang ZW, Hu LM, Yin ZQ, Huang MD, Hu ZB, Shen HB, Shu YQ.
    Asian Pac J Cancer Prev; 2012 Nov; 13(5):2157-62. PubMed ID: 22901187
    [Abstract] [Full Text] [Related]

  • 3. Vitamin D receptor genetic variants are associated with chemotherapy response and prognosis in patients with advanced non-small-cell lung cancer.
    Xiong L, Cheng J, Gao J, Wang J, Liu X, Wang L.
    Clin Lung Cancer; 2013 Jul; 14(4):433-9. PubMed ID: 23522953
    [Abstract] [Full Text] [Related]

  • 4. Clinical outcome of cisplatin-based chemotherapy is associated with the polymorphisms of GSTP1 and XRCC1 in advanced non-small cell lung cancer patients.
    Deng JH, Deng J, Shi DH, Ouyang XN, Niu PG.
    Clin Transl Oncol; 2015 Sep; 17(9):720-6. PubMed ID: 26033426
    [Abstract] [Full Text] [Related]

  • 5. Association of TERT Polymorphisms with Clinical Outcome of Non-Small Cell Lung Cancer Patients.
    Zhao X, Wang S, Wu J, Li X, Wang X, Gao Z, Wu W, Wang H, Wang J, Qian J, Ma K, Li H, Han B, Bai C, Li Q, Liu W, Lu D.
    PLoS One; 2015 Sep; 10(5):e0129232. PubMed ID: 26020272
    [Abstract] [Full Text] [Related]

  • 6. Association of DNA base excision repair genes (OGG1, APE1 and XRCC1) polymorphisms with outcome to platinum-based chemotherapy in advanced nonsmall-cell lung cancer patients.
    Peng Y, Li Z, Zhang S, Xiong Y, Cun Y, Qian C, Li M, Ren T, Xia L, Cheng Y, Wang D.
    Int J Cancer; 2014 Dec 01; 135(11):2687-96. PubMed ID: 24729390
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Predictive and prognostic value of circulating endothelial cells in non-small cell lung cancer patients treated with standard chemotherapy.
    Najjar F, Alammar M, Bachour M, Almalla N, Altahan M, Alali A, Al-Massarani G.
    J Cancer Res Clin Oncol; 2015 Jan 01; 141(1):119-25. PubMed ID: 25037116
    [Abstract] [Full Text] [Related]

  • 9. Comparison of the Efficacy between Pemetrexed plus Platinum and Non-Pemetrexed plus Platinum as First-Line Treatment in Patients with Wild-Type Epidermal Growth Factor Receptor Nonsquamous Non-Small Cell Lung Cancer: A Retrospective Analysis.
    Kang EJ, Min KH, Hur GY, Lee SY, Shim JJ, Kang KH, Oh SC, Seo JH, Kim JS.
    Chemotherapy; 2016 Jan 01; 61(1):41-50. PubMed ID: 26517706
    [Abstract] [Full Text] [Related]

  • 10. Comparison of cisplatin- and carboplatin-based third-generation chemotherapy in 1,014 Chinese patients with advanced non-small-cell lung cancer.
    Luo J, Leaw SJ, Xu Y, Zheng D.
    Med Oncol; 2011 Dec 01; 28(4):1418-24. PubMed ID: 20661668
    [Abstract] [Full Text] [Related]

  • 11. Gemcitabine and vinorelbine followed by weekly docetaxel in patients with advanced non-small-cell lung cancer: a phase II trial of sequential chemotherapy.
    Cobo Dols M, Villar Chamorro E, Alés Díaz I, Gil Calle S, Alcalde García J, Gutiérrez Calderón V, Carabantes Ocón F, Montesa Pino A, Bretón García JJ, Benavides Orgaz M.
    Clin Transl Oncol; 2006 Oct 01; 8(10):742-9. PubMed ID: 17074673
    [Abstract] [Full Text] [Related]

  • 12. Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study.
    Kubota K, Kawahara M, Ogawara M, Nishiwaki Y, Komuta K, Minato K, Fujita Y, Teramukai S, Fukushima M, Furuse K, Japan Multi-National Trial Organisation.
    Lancet Oncol; 2008 Dec 01; 9(12):1135-42. PubMed ID: 19013107
    [Abstract] [Full Text] [Related]

  • 13. Randomized control study of nedaplatin or cisplatin concomitant with other chemotherapy in the treatment of advanced non-small cell lung cancer.
    Li CH, Liu MY, Liu W, Li DD, Cai L.
    Asian Pac J Cancer Prev; 2014 Dec 01; 15(2):731-6. PubMed ID: 24568487
    [Abstract] [Full Text] [Related]

  • 14. Associations of genetic polymorphisms of the transporters organic cation transporter 2 (OCT2), multidrug and toxin extrusion 1 (MATE1), and ATP-binding cassette subfamily C member 2 (ABCC2) with platinum-based chemotherapy response and toxicity in non-small cell lung cancer patients.
    Qian CY, Zheng Y, Wang Y, Chen J, Liu JY, Zhou HH, Yin JY, Liu ZQ.
    Chin J Cancer; 2016 Sep 02; 35(1):85. PubMed ID: 27590272
    [Abstract] [Full Text] [Related]

  • 15. The role of histology with common first-line regimens for advanced non-small cell lung cancer: a brief report of the retrospective analysis of a three-arm randomized trial.
    Scagliotti GV, De Marinis F, Rinaldi M, Crinò L, Gridelli C, Ricci S, Zhao YD, Liepa AM, Peterson P, Tonato M.
    J Thorac Oncol; 2009 Dec 02; 4(12):1568-71. PubMed ID: 20009911
    [Abstract] [Full Text] [Related]

  • 16. Triplet platinum-based combination sequential chemotherapy improves survival outcome and quality of life of advanced non-small cell lung cancer patients.
    Chen LK, Liang Y, Yang QY, Xu F, Zhou NN, Xu GC, Liu GZ, Wei WD.
    Asian Pac J Cancer Prev; 2012 Dec 02; 13(5):1863-7. PubMed ID: 22901137
    [Abstract] [Full Text] [Related]

  • 17. Predictive effect of XPA and XPD polymorphisms on survival of advanced NSCLC patients treated with platinum-based chemotherapy: a three-dimensional (3-D), polyacrylamide gel-based DNA microarray method.
    Cheng H, Qin Q, Sun X, Li F, Sun N, Cheng L, Lu Z, Chen B.
    Technol Cancer Res Treat; 2013 Oct 02; 12(5):473-82. PubMed ID: 23617284
    [Abstract] [Full Text] [Related]

  • 18. Modest reductions in dose intensity and drug-induced neutropenia have no major impact on survival of patients with non-small cell lung cancer treated with platinum-doublet chemotherapy.
    Brunetto AT, Carden CP, Myerson J, Faria AL, Ashley S, Popat S, O'Brien ME.
    J Thorac Oncol; 2010 Sep 02; 5(9):1397-403. PubMed ID: 20644495
    [Abstract] [Full Text] [Related]

  • 19. Non-platinum doublets were as effective as platinum-based doublets for chemotherapy-naïve advanced non-small-cell lung cancer in the era of third-generation agents.
    Jiang J, Liang X, Zhou X, Huang R, Chu Z, Zhan Q.
    J Cancer Res Clin Oncol; 2013 Jan 02; 139(1):25-38. PubMed ID: 22864816
    [Abstract] [Full Text] [Related]

  • 20. Association between polymorphisms of DNA repair genes and survival of advanced NSCLC patients treated with platinum-based chemotherapy.
    Ren S, Zhou S, Wu F, Zhang L, Li X, Zhang J, Xu J, Lv M, Zhang J, Zhou C.
    Lung Cancer; 2012 Jan 02; 75(1):102-9. PubMed ID: 21676483
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.